|11/10/15||Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I|
|CARLSBAD, Calif., Nov. 10, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.8 million milestone payment from Biogen related to the advancement of the ongoing Phase 1/2a study of ISIS-DMPK-2.5Rx in patients with myotonic dystrophy type I (DM1).
"Our collaboration with Biogen has been very productive. ISIS-DMPK-2.5Rx has rapidly advanced into patients with DM1, and we continue to make progress across the board in our drug discovery prog... |
|11/09/15||Isis Reports Financial Results and Highlights for Third Quarter 2015|
|- 2015 Pro Forma Net Income of $25 Million Significantly Increased Over 2014
- Conference Call Webcast Monday, November 9, 11:30 a.m. ET at www.isispharm.com
CARLSBAD, Calif., Nov. 9, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported consolidated financial results for the third quarter of 2015 and highlighted recent progress in advancing its pipeline.
"Our drugs in development have the potential to make fundamental changes in the way diseases are treat... |
|11/08/15||Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs|
|Webcast to review data scheduled for Sunday, November 8 at 1:00 p.m. Eastern Time
CARLSBAD, Calif., and CAMBRIDGE, Mass., Nov. 8, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and its subsidiary, Akcea Therapeutics, today announced positive results from a Phase 2 study of ISIS-APO(a)Rx in which patients with high lipoprotein(a), or Lp(a), achieved reductions in Lp(a) of up to 94 percent, with a mean reduction of 71 percent. Lp(a) is a known driver of cardiovascular disease.... |
|11/06/15||Isis Pharmaceuticals to Present at Upcoming Investor Conferences|
|CARLSBAD, Calif., Nov. 6, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:
24th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2015 in Scottsdale, AZ;
2015 Stifel Healthcare Conference on Wednesday, November 18, 2015 in New York, NY; and
27th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 20... |